EMEA-001712-PIP02-15 - paediatric investigation plan

Biotin

Key facts

• Active Substance:
  Biotin
• Therapeutic area:
  Neurology
• Decision number:
  P/0077/2016
• PIP number:
  EMEA-001712-PIP02-15
• Pharmaceutical form(s):
  Capsule (hard)
• Condition(s) / indication(s):
  Treatment of multiple sclerosis
• Route(s) of administration:
  Oral use
• Contact for public enquiries:

  MEDDAY SAS

  France; Tel. [phone]; Fax [phone]; E-mail: [e-mail]

• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  18/03/2016

Decision

P/0077/2016: EMA decision of 18 March 2016 on the granting of a product specific waiver for biotin (EMEA-001712-PIP02-15)

AdoptedReference Number: EMA/131679/2016